Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cardiff Oncology, Inc. (CRDF : NSDQ)
 
 • Company Description   
Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.

Number of Employees: 33

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.66 Daily Weekly Monthly
20 Day Moving Average: 1,420,675 shares
Shares Outstanding: 66.53 (millions)
Market Capitalization: $243.49 (millions)
Beta: 1.52
52 Week High: $5.64
52 Week Low: $2.01
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.11% -4.37%
12 Week 53.78% 29.01%
Year To Date -15.67% -21.01%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11055 FLINTKOTE AVENUE
-
SAN DIEGO,CA 92121
USA
ph: 858-952-7570
fax: -
ir@cardiffoncology.com https://cardiffoncology.com
 
 • General Corporate Information   
Officers
Mark Erlander - Chief Executive Officer
Rodney S. Markin - Chairman
James Levine - Chief Financial Officer
James O. Armitage - Director
Mani Mohindru - Director

Peer Information
Cardiff Oncology, Inc. (CORR.)
Cardiff Oncology, Inc. (RSPI)
Cardiff Oncology, Inc. (CGXP)
Cardiff Oncology, Inc. (BGEN)
Cardiff Oncology, Inc. (GTBP)
Cardiff Oncology, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 14147L108
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 66.53
Most Recent Split Date: 2.00 (0.17:1)
Beta: 1.52
Market Capitalization: $243.49 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.78 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.44
Price/Cash Flow: -
Price / Sales: 414.09
EPS Growth
vs. Year Ago Period: 9.09%
vs. Previous Quarter: 4.76%
Sales Growth
vs. Year Ago Period: -46.83%
vs. Previous Quarter: -27.81%
ROE
06/30/25 - -
03/31/25 - -76.45
12/31/24 - -73.99
ROA
06/30/25 - -
03/31/25 - -62.85
12/31/24 - -60.54
Current Ratio
06/30/25 - -
03/31/25 - 6.22
12/31/24 - 7.08
Quick Ratio
06/30/25 - -
03/31/25 - 6.22
12/31/24 - 7.08
Operating Margin
06/30/25 - -
03/31/25 - -8,308.50
12/31/24 - -6,641.96
Net Margin
06/30/25 - -
03/31/25 - -8,308.50
12/31/24 - -6,641.96
Pre-Tax Margin
06/30/25 - -
03/31/25 - -8,308.50
12/31/24 - -6,651.68
Book Value
06/30/25 - -
03/31/25 - 1.07
12/31/24 - 1.86
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©